Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAIN study: trametinib in NF1-related symptomatic plexiform neurofibromas
2019-001317-16Phase 2Active
- Sponsor
- Erasmus MC
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trametinib in neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN), sponsored by Erasmus MC. Primary endpoint: Tumor volume response by volumetric MRI. Started Oct 2019; status: active.
02
Drugs
trametinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on 2019-001317-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001317-16.